Olaparib (Lynparza®) adjuvant treatment of early breast cancer. HTA ID: 22065

Assessment Status NCPE assessment ongoing
HTA ID 22065
Drug Olaparib
Brand Lynparza®
Indication As monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.
Assessment Process
Rapid review commissioned 26/10/2022
Rapid review completed 20/10/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of olaparib compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 26/10/2022
Pre-submission consultation with Applicant 13/12/2022
Full submission received from Applicant 27/09/2023
Preliminary review sent to Applicant 09/05/2024
NCPE assessment re-commenced 06/06/2024